Atlanta, Ga. (July 28, 2025) – Eyal Meiri, M.D., a Piedmont Oncology medical oncologist who cares for patients with gastrointestinal (GI) cancers, will activate two high priority clinical trials for patients with rare but deadly cancers.
“We are excited to offer these innovative trials to cancer patients in Georgia and beyond,” Dr. Meiri said. “These two trials involve the delivery of new types of targeted therapies. These targeted therapies are designed to destroy cancer cells without damaging healthy ones. This is of great benefit to the overall health and wellness of our patients.”
The DESTINY-BTC01 trial is for patients with biliary tract cancer and is a phase 3 trial. The worldwide goal is to enroll 620 patients. The biliary tract connects the liver, gallbladder and pancreas to the top of the small intestine, or duodenum. The study is estimated to be completed in June 2027.
About 8,000 people in the United States are diagnosed with biliary duct cancer each year, according to the American Cancer Society (ACS). The five-year survival rate for all stages combined for biliary tract cancer is only 9 percent. Generally, it affects an older population, with the average age with this cancer in the United States being 70. This trial involves the use of a monoclonal antibody, which was employed successfully in a smaller trial.
The NETTER-3 study will enroll patients with gastroenteropancreatic neuroendocrine tumors, known as GEP-NETs, which originate within the gastrointestinal tract and pancreas. The trial will open on May 6 and run through June 23, 2028. Enrollment will occur at Piedmont Atlanta Hospital.
The five-year survival rate for patients across all stages of pancreatic neuroendocrine tumors is 53 percent, according to ACS. About 12,000 new cases of neuroendocrine tumors are diagnosed each year. This trial involves a radioisotope in medicine form to treat the cancer.
Dr. Meiri earned his medical degree from University of Toronto and completed his residency at Sinai Hospital of Detroit. He is fellowship-trained in oncology and hematology and is board certified in Internal Medicine and Medical Oncology. Dr. Meiri has been practicing medicine for over 33 years and specializes in the care of patients with GI cancers or neuroendocrine tumors.